IMTX vs WVE
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
IMTX exhibits severe fundamental distress, highlighted by a Piotroski F-Score of 1/9, indicating critical weakness in financial health and operational efficiency. While the company maintains an exceptionally strong liquidity position (Current Ratio of 11.72) and low debt, these are overshadowed by a catastrophic 64.90% year-over-year decline in revenue and deeply negative gross margins (-280.87%). The stock currently trades at a speculative premium with a Price/Sales ratio of 28.98 despite shrinking top-line growth. Any potential upside is driven by analyst price targets ($18.75) rather than current financial performance.
WVE exhibits severe financial distress from a deterministic standpoint, highlighted by a critical Piotroski F-Score of 1/9. While the company maintains a strong liquidity position with a current ratio of 6.47 and negligible debt, these are offset by a catastrophic 79.4% decline in year-over-year revenue and an operating margin of -327.44%. There is a stark divergence between the 'Strong Buy' analyst consensus and the bearish reality of insider selling by the CEO and CFO, alongside a recent 37% price collapse. The valuation is purely speculative, as evidenced by a Price/Sales ratio of 32.21 in the face of shrinking revenues.
Compare Another Pair
Related Comparisons
IMTX vs WVE: Head-to-Head Comparison
This page compares Immatics N.V. (IMTX) and Wave Life Sciences Ltd. (WVE) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.